Petros Grivas, MD, PhD
14 Years of Experience
Physician
Seattle Cancer Care Alliance
Seattle Cancer Care Alliance
Associate Professor
University of Washington School of Medicine
University of Washington School of Medicine
Clinical Director, Genitourinary Cancers Program
UW Medicine
UW Medicine
Clinical expertise
Genitourinary cancers
Genitourinary cancers
Located at
“At SCCA, I belong to a family of innovative, patient-centered providers.”
—
Dr. Grivas
What drew you to oncology?
Ever since I was young, I’ve wanted to help other people. I knew a family friend who was a physician, and he served as a great example of how I could channel this desire, combining knowledge and compassion so that I could be of service to a community. I chose to focus on genitourinary cancers because they’re a set of very common diseases affecting the urinary tract and male reproductive system, so I felt pursuing this specialty would allow me to make a difference in the lives of many. I see this area of oncology as an opportunity to bring together my interest in innovative research and patient care.
Specialties and clinical expertise
The branch of medicine a provider practices and their areas of focus
Medical Oncology
Medical Oncology
Genitourinary cancers
I am a board-certified medical oncologist who specializes in treating patients with genitourinary cancers, such as bladder cancer and prostate cancer. My background includes leading the bladder/urothelial cancer program at the Cleveland Clinic and caring for patients at the University of Michigan, Ann Arbor. Currently, I serve as the director of UW Medicine's Genitourinary Cancers Program, giving frequent lectures, educating other oncologists and trainees and publishing novel research. I also conduct clinical trials, one of which led to the FDA approval of new drugs for bladder and urothelial cancer.
Diseases treated
How do you like to work with patients?
I am dedicated to providing outstanding cancer care, which to me means taking a personalized approach with each patient and being efficient with time and resources. I hope to learn what brought you in and what your goals and expectations are — both for each visit and in the long term. While I bring a wealth of knowledge about genitourinary cancers and the latest research developments, I also believe that the little things, like a warm smile and a conversation held eye-to-eye, matter a great deal.
Medical Degree
University of Patras School of Medicine, Greece
University of Patras School of Medicine, Greece
Residency
Drexel University College of Medicine/Hahnemann University Hospital, Internal Medicine
Drexel University College of Medicine/Hahnemann University Hospital, Internal Medicine
Fellowship
University of Michigan, Hematology-Oncology
University of Michigan, Hematology-Oncology
Board Certification
Medical Oncology, 2013, American Board of Internal Medicine; Internal Medicine, 2010, American Board of Internal Medicine
Medical Oncology, 2013, American Board of Internal Medicine; Internal Medicine, 2010, American Board of Internal Medicine
Other
PhD, University of Patras School of Medicine, Greece
PhD, University of Patras School of Medicine, Greece
Languages
English, Greek, Italian
Your care team
At SCCA, you receive care from a team of providers with extensive experience in your disease. Your team includes doctors, a team coordinator, a registered nurse, an advanced practice provider and others, based on your needs. You also have access to experts like nutritionists, social workers, acupuncturists, psychiatrists and more who specialize in supporting people with cancer or blood disorders.
Registered nurse (RN)
Your nurse manages your care alongside your physician and assists with care procedures and
treatments.
Team coordinator (TC)
Your team coordinator works closely with you and your physician and serves as your scheduler.
Clinical trials
We make promising new treatments available to you through studies called clinical trials led by SCCA doctors. Many of these trials at SCCA have led to FDA-approved treatments and have improved standards of care globally. Together, you and your doctor can decide if a study is right for you.
CV301 Combined With PD-1/L1 Blockade in Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer
Study No:
NCT03628716
Phase:
Phase II
Phase II Open Label, Study of IMMU-132 in Metastatic Urothelial Cancer
Study No:
NCT03547973
Phase:
Phase II
Pembrolizumab in Treating Patients With Locally Advanced Bladder Cancer (AMBASSADOR)
Study No:
NCT03244384
Phase:
Phase III
Basket Trial in Solid Tumors Harboring a Fusion of FGFR1, FGFR2 or FGFR3- (FUZE Clinical Trial)
Study No:
NCT03834220
Phase:
Phase II
Press and news
SCCA providers are often asked to give their medical advice for press and news publications. Read articles by or about this SCCA provider.
“Huge Effort” Underway to Identify Biomarkers in Urothelial Cancer
By Healio -
Published April 22, 2019
Dr. Grivas on Checkpoint Inhibitors in Localized Bladder Cancer
By OncLive -
Published February 6, 2019
Publications
Many of our SCCA physicians conduct ongoing research to improve standards of patient care. Their work is evaluated by other physicians and selected for publication to the United States National Library of Medicine, the largest medical library in the world. See scientific papers this SCCA provider has written.
Non-invasive diagnosis and monitoring of urothelial bladder cancer: are we there yet?
Cost-effectiveness of Pembrolizumab for Patients with Advanced, Unresectable, or Metastatic Urothelial Cancer Ineligible for Cisplatin-based Therapy.